Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.
Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020
Loading statistic...
Basic Account
Get to know the platform
You only have access to basic statistics.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic COVID-19-related research market cap changes in biopharma companies Feb 2020
- Premium Statistic Average peak sales forecast per new biopharmaceutical asset 2013-2022
- Basic Statistic U.S. venture investments in infectious disease companies 2006-2023
- Basic Statistic Top pharma companies worldwide by number of originated drugs 2024
- Premium Statistic Clinical CRO market share worldwide by company 2016
- Premium Statistic Members of EFPIA's pharmaceutical R&D spending 1990-2022
- Premium Statistic Merck & Co.'s top-selling drugs 2023
- Premium Statistic Merck & Co - expenditure on research and development 2006-2023
- Basic Statistic Rate of return on biopharma R&D late stage pipeline 2013-2022
- Basic Statistic Projected top pharmaceutical companies based on sales 2023
About the region
10
- Basic Statistic Number of COVID-19 treatment vaccine trials worldwide by phase June 2022
- Basic Statistic Number of COVID-19 treatment vaccine trials worldwide by type June 2022
- Basic Statistic Number of COVID-19 drugs in development worldwide by phase June 2022
- Premium Statistic Number of registered COVID-19 studies worldwide Apr 2020 - Dec 2022, by region
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Basic Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2023-2028
- Basic Statistic Biotechs: duration of COVID-19 response compared to previous health threats 2003-2019
- Premium Statistic Global AI-enabled drug discovery and clinical trials market by region 2030
- Premium Statistic Leading global contract research organizations based on revenue 2022
- Basic Statistic Percentage return on R&D among mid cap biopharma companies 2013-2020
Selected statistics
10
- Basic Statistic Merck & Co cash dividends declared 2006-2023
- Basic Statistic Sanofi's total assets 2007-2023
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2023
- Basic Statistic Merck & Co total assets 2009-2023
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2023
- Premium Statistic Sales of Johnson & Johnson 2006-2023 by region
- Basic Statistic GSK's operating profit by division 2006-2021
- Premium Statistic Johnson & Johnson's number of employees 2004-2023
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Premium Statistic Global pharmaceutical pipeline by therapy area 2013-2017
Other regions
10
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Basic Statistic Spending on R&D from pharmaceutical industry in Canada 2004-2022
- Premium Statistic Revenue generated by high-tech companies through new products 2021, by industry
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Basic Statistic Share of sales attributable to new active substances launched 2016-2020 by country
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Mexico: pharmaceutical expenditure 2012-2018
- Basic Statistic Latino COVID-19 deaths vs population in select U.S. states as of June 23, 2020
- Basic Statistic UK pharmaceutical businesses: R&D expenditure 2002-2021
- Premium Statistic R&D spending in the pharmaceutical industry in Argentina 2016-2020
Related statistics
10
- Premium Statistic Number of cumulative orphan designations accepted in the U.S. 2003-2018
- Basic Statistic R&D cost to develop new pharmaceutical compounds 2010-2020
- Premium Statistic Number of biopharmaceutical deals worldwide 2016-2020, by type
- Basic Statistic Number of cell and gene therapy deals worldwide 2016-2020, by type
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Premium Statistic CRO market size worldwide forecast 2028
- Basic Statistic Presumed benefits of participation in clinical trials among adults worldwide in 2019
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Basic Statistic Global biologics discovery market worldwide by phase 2016-2025
- Premium Statistic Reasons why clinical trial organizations use direct-to-patient distribution 2016
Further related statistics
10
- Pfizer's ad spending 2006-2023
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2023
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
Further Content: You might find this interesting as well
Statistics
- Pfizer's ad spending 2006-2023
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2023
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
Vantage. (February 27, 2020). Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020 [Graph]. In Statista. Retrieved May 09, 2024, from https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/
Vantage. "Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020." Chart. February 27, 2020. Statista. Accessed May 09, 2024. https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/
Vantage. (2020). Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020. Statista. Statista Inc.. Accessed: May 09, 2024. https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/
Vantage. "Share Price Changes of Select Biopharmaceutical Companies Involved in Coronavirus (Covid-19) Research from January 20 to February 25, 2020." Statista, Statista Inc., 27 Feb 2020, https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/
Vantage, Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020 Statista, https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/ (last visited May 09, 2024)
Share price changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020 [Graph], Vantage, February 27, 2020. [Online]. Available: https://www.statista.com/statistics/1103603/coronavirus-related-share-price-changes-in-biopharma/